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Doxycycline Indirectly Inhibits Proteolytic Activation
of Tryptic Kallikrein-Related Peptidases and
Activation of Cathelicidin
Kimberly N. Kanada1, Teruaki Nakatsuji1 and Richard L. Gallo1
The increased abundance and activity of cathelicidin and kallikrein 5 (KLK5), a predominant trypsin-like serine
protease (TLSP) in the stratum corneum, have been implicated in the pathogenesis of rosacea, a disorder treated
by the use of low-dose doxycycline. Here we hypothesized that doxycycline can inhibit activation of tryptic KLKs
through an indirect mechanism by inhibition of matrix metalloproteinases (MMPs) in keratinocytes. The
capacity of doxycycline to directly inhibit enzyme activity was measured in surface collections of human facial
skin and extracts of cultured keratinocytes by fluorescence polarization assay against fluorogenic substrates
specific for MMPs or TLSPs. Doxycycline did inhibit MMP activity but did not directly inhibit serine protease
activity against a fluorogenic substrate specific for TLSPs. However, when doxycycline or other MMP inhibitors
were added to live keratinocytes during the production of tryptic KLKs, this treatment indirectly resulted in
decreased TLSP activity. Furthermore, doxycycline under these conditions inhibited the generation of the
cathelicidin peptide LL-37 from its precursor protein hCAP18, a process dependent on KLK activity. These results
demonstrate that doxycycline can prevent cathelicidin activation, and suggest a previously unknown
mechanism of action for doxycycline through inhibiting generation of active cathelicidin peptides.
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INTRODUCTION
Cathelicidin is one of the most well-characterized antimi-
crobial peptides (AMPs) found in the human skin. Because of
its direct antimicrobial action against a wide range of bacteria
(Larrick et al., 1995b), the release of these peptides is
responsible in part for innate defense against infectious
pathogens. Human cathelicidin is produced as an inactive
precursor protein with a mass of 18 kDa, and is named
hCAP18 (Larrick et al., 1995a). Posttranscriptional processing
cleaves the C-terminal cathelin domain from hCAP18 and
produces active AMPs such as a peptide composed of 37
amino acids beginning with two leucines, named LL-37.
Recently, our group showed that stratum corneum trypsin-
like serine proteinases (TLSPs) of the kallikrein (KLK)-related
peptidase family participate in the proteolytic activation of
hCAP18 to LL-37 in the skin (Yamasaki et al., 2006, 2007).
KLKs are present in virtually all tissues and fluids of the body
at varying levels of expression. KLK5, originally denoted as
stratum corneum tryptic enzyme, is the most predominant
TLSP in the stratum corneum of human skin (Brattsand and
Egelrud, 1999). KLK5 is highly expressed in the stratum
granulosum, and is then transported by lamellar granules and
accumulates in the stratum corneum (Ishida-Yamamoto et al.,
2005). KLK14 is also a TLSP found in human stratum corneum
(Stefansson et al., 2006), which may contribute to proteolytic
activation of hCAP18 to LL-37 in addition to KLK5. KLKs are
released as inactive preproenzymes with a signal peptide
removed upon secretion and profragment removed during
activation (Kantyka et al., 2011). Activation entails either
autoactivation and/or activation by other KLKs in a cascade-
like manner, or removal of the profragment by enzymes
such as matrix metalloproteinases (MMPs) or other endo-
peptidases (Ryu et al., 2002; Lundwall and Brattsand, 2008;
Sotiropoulou et al., 2009). For example, pro-KLK4 undergoes
proteolytic activation by MMP-3 and MMP-20 (Ryu et al.,
2002; Beaufort et al., 2010; Chun et al., 2010). Pro-KLK7 is
processed by another epidermal metalloproteinase, meprin b,
before activation of pro-KLK7 by tryptic enzymes (Ohler
et al., 2010). Thus, we have hypothesized that MMPs may
stimulate KLK activity and thus indirectly catalyze proteolytic
activation of hCAP18 to LL-37.
The cathelicidin peptide LL-37 not only has the capacity to
kill microbes but can also modify host immunity and growth
responses by promoting leukocyte chemotaxis (De et al.,
2000), angiogenesis (Koczulla et al., 2003), and altering
expression of extracellular matrix components (Wolf et al.,
2001; Park et al., 2009). Recent clinical observations indicate
that abnormal production of LL-37 in the skin is implicated in
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a wide variety of inflammatory skin diseases including
psoriasis (Lande et al., 2007) and atopic dermatitis (Ong
et al., 2002). In addition, abnormal expression of KLK5 was
observed in rosacea skin, causing aberrant proteolytic
activation of hCAP18 to the long peptide form of cathelicidin
(LL-37) that is not found in large amounts on normal
noninflamed skin (Yamasaki et al., 2007). KLK5 itself triggers
a proinflammatory microenvironment independently of
external stimuli by inducing cytokine overexpression and
defective stratum corneum adhesion (Briot et al., 2009;
Voegeli et al., 2009). It also affects dermal matrix and
vascular remodeling via the digestion of corneodesmosin,
desmocollin 1, desmoglein 1 (Caubet et al., 2004; Jiang et al.,
2011), collagens type I, II, III, and IV, fibronectin, and laminin
(Michael et al., 2005). Therefore, blocking the activity of
tryptic KLKs may have a therapeutic capacity to relieve
inflammation on two levels.
Doxycycline has been reported to nonselectively inhibit
MMPs by binding to zinc and calcium atoms and causing
conformational changes and loss of enzymatic activity
(Garcia et al., 2005). In addition to this direct inhibitory
activity, doxycycline has been reported to suppress gene
expression of MMPs in human corneal epithelial cells (Li
et al., 2004), human umbilical vein endothelial cells
(Hanemaaijer et al., 1998), and skin keratinocytes (Uitto
et al., 1994). Doxycycline has also been shown to have
efficacy in the systemic treatment of rosacea at subantimi-
crobial doses (40mgday–1), a dose below the conventional
level (100–200mgday–1) used in antimicrobial action (Kort-
ing and Schollmann, 2009a). These observations suggest that
doxycycline may exert its therapeutic effects in rosacea by a
mechanism that does not include alteration of microbial
abundance. However, the precise mechanism of action of
doxycycline in rosacea treatment is still unknown.
In this study, we investigated whether the ability of
doxycycline to inhibit MMPs could influence the activity of
tryptic KLKs and the activation of cathelicidin in human
keratinocytes. Our findings offer a hypothesis that may
explain the therapeutic potential of doxycycline, and could
have broad implications for the treatment of disease states
where overexpression of LL-37 has a role in inflammation.
RESULTS
Doxycycline inhibits MMP activity in human skin and cultured
keratinocytes
Prior observations that doxycycline nonselectively inhibits
MMP activity led us to investigate the ability of doxycycline
to attenuate the activity of cutaneous MMPs. Surface material
from normal facial skin of healthy volunteers was collected by
tape stripping, and enzymes were extracted. Cumulative
activity of MMPs was measured by fluorescence polarization
assay using an MMP-specific substrate. Enzymatic activity
collected by tape strip catalyzed increased processing of the
MMP substrate, and this was detected by increased fluorescent
emission over time. Compared with skin surface protein extract
treated with vehicle, total enzyme activity was significantly
decreased when facial tape-strip proteins were treated with
doxycycline at a concentration of 225mM (Figure 1a). As
expected for a kinetic assay, the percentage of total inhibition
of MMP product by doxycycline, calculated every hour, grew
linearly throughout the time period to 425% inhibition at
24hours (Figure 1b). These observations made in a cell-free
system of protein extracted from human facial skin suggested
that doxycycline had a direct inhibitory effect on human
cutaneous MMP activity.
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Figure 1. Doxycycline inhibits human cutaneous and normal human
epidermal keratinocyte (NHEK) matrix metalloproteinase (MMP) activity
in vitro. (a) Tape-strip samples were obtained from normal human facial
skin, and total protein was extracted and normalized to a final protein
concentration of 115mgml–1. MMP activity was measured in relative
fluorescence units (RFU) using fluorogenic substrate (5 mM) sensitive to
most MMP enzymes (MMP-1, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12,
MMP-13, MMP-14, MMP-16, and MMP-20). Total-MMP activity of enzymatic
extract treated with doxycycline (225 mM) was decreased throughout
incubation as compared with vehicle control. *Po0.05, **Po0.01 by
Student’s t-test, versus vehicle. (b) Doxycycline inhibition of total MMP
activity, expressed as percent inhibition (%) at every hour, increased linearly
throughout. (c) Incubating NHEK cell lysate with doxycycline (225 mM) for
18 hours significantly attenuated total MMP activity, showing direct inhibitory
action. SB3CT (5 mM), a selective inhibitor of MMP-2 and MMP-9, and
GM6001 (25 mM), a nonselective MMP inhibitor, were used as positive
controls and showed similar effect. Vehicle control was 0.1% (v/v) DMSO.
(d) Total MMP activity in NHEK-conditioned media (for secreted MMPs) was
measured with fluorogenic substrate in the presence of calcium and zinc.
All three inhibitors suppressed total MMP activity. (e) Cell lysate was assayed
for MMP-2 activity in the presence of zinc ion required for its enzymatic
activity as described in the Materials and Methods. (f) Conditioned medium
was assayed for MMP-2 activity as in e. *Po0.05, **P o0.01, ***Po0.005
by Student’s t-test, versus vehicle or control.
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To determine whether the observed inhibitory effect of
doxycycline on extracted human facial skin samples could be
also measured in cultured keratinocytes, MMP activity was
determined after doxycycline addition to lysates of normal
human epidermal keratinocytes (NHEKs), or addition to
culture media. Both total-MMP and MMP-2 activities in cell
lysates (demonstrating cellular MMPs) and conditioned
media (demonstrating secreted MMPs) were significantly
suppressed (Figure 1c–f). At the concentrations used here,
the degree of inhibition of MMP activity in the cell-associated
fraction was similar between doxycycline (half-maximal
inhibitory concentration (IC50)¼15 mM) and known inhibitors
of MMPs, SB-3CT (IC50¼ 185–2,900 nM), a selective inhibitor
of MMP-2 and MMP-9, and GM6001 (IC50¼0.4 nM), a
nonselective MMP inhibitor.
Serine protease inhibitors decrease TLSP activity in the stratum
corneum of human skin in vitro
We next verified that serine protease inhibitors could directly
attenuate the enzymatic activity in the stratum corneum of
healthy skin using a similar fluorescence polarization assay
and a TLSP-specific fluorogenic substrate. Because stratum
corneum TLSPs, such as tryptic KLKs, are implicated in the
direct activation of human cathelicidin precursor protein
hCAP18 to mature peptide LL-37 on the skin surface
(Yamasaki et al., 2006), we used Boc-Phe-Ser-Arg-AMC, a
fluorogenic substrate specific for TLSPs, to establish this
assay. As shown in Figure 2a, addition of purified tissue KLK
rapidly cleaved the substrate to generate maximal fluorogenic
product, and the activity of tissue-purified KLK was sig-
nificantly inhibited for up to 20 hours by AEBSF (4-(2-
Aminoethyl) benzenesulfonyl fluoride hydrochloride), an
irreversible serine protease inhibitor. This effect was also
demonstrable in the proteins extracted from tape-strip
samples collected from the facial skin of healthy volunteers.
Protein extract from facial tape strips demonstrating TLSP
activity reached a peak at 2 hours and could be suppressed in
the presence of AEBSF (Figure 2b). In a similar manner,
aprotinin, a competitive serine protease inhibitor, was also
assessed for its ability to diminish TLSP activity in normal
facial skin protein extract. Aprotinin strongly attenuated
cutaneous total protease activity as compared with vehicle
(Figure 2c), suggesting a predominance of serine proteases on
the human skin surface. These data suggest that much of the
total enzymatic activity detected by tape stripping human
facial skin is serine protease in nature.
Doxycycline directly inhibits MMP activity, but indirectly
inhibits TLSP activity
Having established sensitive direct assays of human skin
MMP and TLSP activity, we next sought to examine the
inhibitory effects of doxycycline on these enzymes in human
keratinocytes. The activities of these enzymes were first
measured directly in lysates of NHEKs where the final
proteolytic activation of tryptic KLKs could proceed before
the addition of inhibitors. Final enzyme activity was
determined in the presence of various concentrations of
doxycycline (0, 56.25, 112.5, 225, and 450mM) added to the
NHEK lysate. The ability of doxycycline to diminish cellular
enzyme activity was reflected in the change in fluorescence
emitted at each doxycycline concentration compared with
baseline (0 mM doxycycline). Similar to results from facial skin
tape strips, total-MMP and MMP-2 activities were directly
inhibited in NHEK lysate by doxycycline in a dose-dependent
manner (Figure 3a and b), with 90% inhibition occurring at a
doxycycline concentration of 225mM. In contrast, TLSP
enzymatic activity was not significantly inhibited by doxycy-
cline until exposed to the highest dose of doxycycline
(475 mM), and even then abundant activity remained com-
pared with control (Figure 3c). Therefore, we used 225 mM of
doxycycline for the following experiments as a dose that
effectively directly inhibited MMP activity but not TLSP
activity.
Live NHEKs in culture were then exposed to doxycycline
to test the effect of this drug, or other MMP inhibitors, on the
generation of nascent TLSP activity from live cells. Under
these conditions, a concentration of doxycycline that had no
direct inhibitory effect on NHEK TLSP activity (225 mM)
significantly attenuated both cellular (Figure 4a) and secreted
(Figure 4b) TLSP activity generated by living cells. Incubating
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Figure 2. Serine protease inhibitors inhibit cutaneous trypsin-like serine protease (TLSP) activity in vitro. (a) Tissue-purified kallikrein from porcine pancreas
(50mgml–1) was incubated with and without 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF; 250mM), an irreversible serine protease inhibitor.
AEBSF directly inhibited TLSP activity as compared with vehicle control as measured using a fluorogenic TLSP-specific substrate (2.5mM) to assay TLSP activity
(relative fluorescence units (RFU)). (b) Tape-strip samples from normal facial skin were obtained, and total enzymes were extracted. Enzymatic extract was
incubated with and without AEBSF to gauge the serine protease inhibitor’s ability to attenuate cutaneous TLSP activity (RFU). Compared with vehicle control,
AEBSF inhibited cutaneous TLSP activity throughout 20 hours of incubation. (c) Tape-strip samples from normal facial skin were measured with EnzChek
Protease Assay Kit (Invitrogen) in the absence of inhibitor (vehicle) and in the presence of aprotinin (50 mgml–1), a competitive inhibitor for serine proteases.
Aprotinin strongly attenuated cutaneous total protease activity.
www.jidonline.org 1437
KN Kanada et al.
Doxycycline Inhibits Cathelicidin Activation
keratinocytes with specific MMP inhibitors SB-3CT and
GM6001 also resulted in lower TLSP activity. Thus, although
there was minimal effect on TLSP activity when doxycycline
was added directly to cells under conditions in which KLKs
were already activated, addition to live cells resulted in
decreased serine protease activity. These results suggested
that doxycycline indirectly suppressed tryptic KLK activity in
keratinocytes by blocking the action of MMPs.
Doxycycline pretreatment to live NHEK inhibits the processing
of hCAP18 to LL-37
To evaluate the ability of doxycycline to inhibit processing
of cathelicidin, full-length recombinant cathelicidin hCAP18
was required for functional analysis, as endogenous
production of cathelicidin by NHEK is too little to
detect by standard western blotting techniques. Complemen-
tary DNA encoding full-length hCAP18 was cloned
into the pEcoli expression vector system. This system
generated fusion proteins with an N-terminal peptide of
5 kDa containing a 6 HN purification tag. Cultures of
BL21 (DE3) bacteria transformed with pEcoli-hCAP18 were
used for expression following IPTG (isopropyl b-D-1-thioga-
lactopyranoside) induction. A band of B18 kDa, which
corresponds to hCAP18, was detected and confirmed by
western blot analysis using antibody against LL-37
(Figure 5).
To evaluate the ability of doxycycline to attenuate live
NHEK processing of full-length recombinant hCAP18,
we differentiated NHEK in high calcium conditions known
to upregulate expression of KLK5 (Morizane et al., 2010).
Identical amounts of rhCAP18 were added to all
cultures. Western blot analysis for LL-37 demonstrated that
under normal conditions a portion of recombinant hCAP18
added was cleaved to a size consistent with LL-37
(Figure 5a, lane 1). If NHEKs were pretreated with
doxycycline (225 mM) and then incubated with an identical
amount of added recombinant hCAP18, proteolytic proces-
sing was diminished as evidenced by the disappearance of
the LL-37 band (Figure 5a, compare lane 1 with lane 3).
Western blot analysis for LL-37 was also performed on equal
fractions of culture media overlying NHEKs to compare with
the results seen with the cell fraction. Recombinant hCAP18
added to the media of untreated cells became associated with
the cell fraction (Figure 5a, lane 1), resulting in a decreased
amount of rhCAP18 present in the conditioned media (Figure
5b, lane 1). However, when pretreated with doxycycline,
hCAP18 persisted in the media (Figure 5b, lane 3), and was
similar in final processed size to that detected in the cell
fraction (Figure 5a, lane 3). Taken together, these results show
that doxycycline added to live NHEKs altered the proteolytic
cleavage of hCAP18 and association with keratinocytes.
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Figure 3. Doxycycline directly inhibits keratinocyte matrix metalloproteinase (MMP) but not trypsin-like serine protease (TLSP) activity. To examine the
concentration at which doxycycline directly inhibits MMP and TLSP in normal human epidermal keratinocytes (NHEKs), MMP and TLSP activities in
NHEK lysates were determined in the presence of various concentrations of doxycycline (0, 56.25, 112.5, 225, and 450 mM). Cell lysate from NHEKs was
measured for baseline catalysis of enzyme-specific substrates and then compared with catalysis in the presence of differing concentrations of doxycycline.
Relative enzymatic activity is represented as percentage of no doxycycline control (100%). (a, b) Total-MMP catalysis is directly inhibited in a dose-dependent
manner by direct addition of doxycycline to NHEK extracts. (c) In contrast to the inhibition of MMP activity, maximum inhibition of TLSP activity by
doxycycline did not exceed 50% and was not significant at a concentration of doxycycline that was effective at inhibition of MMP activity (225 mM).
*Po0.05, ***Po0.005 by Student’s t-test, versus vehicle or control.
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Figure 4. Doxycycline inhibits cellular and secreted trypsin-like serine
protease (TLSP) activity of live keratinocytes. (a) To examine the activity of
doxycycline on TLSP activity produced by live normal human epidermal
keratinocytes (NHEKs), cells were cultured in media containing doxycycline
(225mM) for 18 hours. The matrix metalloproteinase (MMP) inhibitors
SB3CT (5 mM) and GM6001 (25 mM) were used as positive controls for MMP
inhibition. TLSP activity in cell lysate following culture with doxycycline was
determined with TLSP-specific substrate (relative fluorescence units (RFU)).
Doxycycline significantly attenuated cellular TLSP activity generated by live
cells. Incubating cells with SB-3CT and GM6001 also significantly decreased
cellular TLSP activity. (b) Secreted TLSP activity was similarly assayed in
NHEK conditioned media. Doxycycline significantly decreased secreted TLSP
activity. The inability of doxycycline to inhibit TLSP activity when directly
added to enzyme extracts (Figure 3c) suggests that the inhibition induced in
live cells is by an indirect mechanism and is related to the capacity to inhibit
MMPs. *Po0.05, **P o0.01 by Student’s t-test, versus vehicle or control.
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DISCUSSION
As a physical and chemical barrier, the skin is reliant on
proteases to control differentiation and turnover of keratino-
cytes, process structural components, and activate AMPs. The
latter function combats bacterial challenges and provides fast
and first-line protection against microorganisms. Endogenous
and exogenous proteases such as KLKs, MMPs, matriptases,
caspases, and proteases derived from microorganisms are in
dynamic balance with protease inhibitors such as SERPINs,
LEKTI, elafin, and cystatins to regulate desquamation of the
stratum corneum (Egelrud, 2000) and activation of AMPs
(Yamasaki et al., 2006; Eissa et al., 2011). The mechanisms
that regulate this network of proteases in the epidermis are an
important area of investigation not only to understand their
normal physiology and interplay, which allows for epidermal
homeostasis, but also because changes in the proteolytic
balance in the skin can result in inflammation, ichthyosis,
and other skin disease states such as Netherton syndrome
(Meyer-Hoffert, 2009; Sales et al., 2010).
Dysregulation of AMPs, such as cathelicidin that is
activated by proteases, has an important role in the
pathogenesis of psoriasis, atopic dermatitis, and rosacea.
Whereas skin in atopic dermatitis demonstrates decreased
cathelicidin expression and increased susceptibility to super-
infection, overabundant and abnormal production of cathe-
licidin in rosacea and psoriasis is implicated in the cutaneous
inflammation seen in these disease states because of the
immune-modifying ability of LL-37 (Schauber et al., 2008). In
this study, to better understand the role of LL-37 in rosacea,
we examined the influence of a drug commonly used in
rosacea therapy, our hypothesis being that a drug that
ameliorates the inflammation of rosacea may work through
normalization of cathelicidin processing. We identified
both doxycycline and serine protease inhibitors as capable
of inhibiting key proteolytic enzymes in the cascade
that activates cathelicidin to the inflammatory peptide
LL-37. In human skin tape-strip samples, and both keratino-
cyte lysates and media, doxycycline inhibited MMP activity
but did not attenuate TLSP activity at a concentration
that suppressed 90% of the MMP activity. However, when
doxycycline or MMP-specific inhibitors were added to live
keratinocytes in culture, this resulted in a decrease in
TLSP activity. As these do not directly suppress the activity
of KLK5 or other serine proteases that contribute to the TLSP
activity measured, we conclude that the capacity of
doxycycline to function as a MMP inhibitor indirectly
resulted in a decrease in TLSP activity.
The significance of the capacity of doxycycline to inhibit
TLSP action was seen upon assay of cathelicidin enzymatic
processing by keratinocytes. The use of recombinant hCAP18
protein revealed that doxycycline decreased the proteolytic
processing of hCAP18 to LL-37 (Figure 5). As this step is
dependent on the activity of stratum corneum tryptic KLKs,
but because doxycycline had little effect on directly inhibit-
ing these serine proteases at the concentrations tested, we
conclude that doxycycline functioned indirectly by prevent-
ing tryptic KLK activation by MMPs. This is an important step,
as when mammalian cathelicidin is produced as an 18-kDa
precursor proprotein, hCAP18, it is biologically inactive until
it is cleaved into active LL-37 or other active peptides. Thus,
the chain of proteolytic activation implicates MMPs as
indirect mediators of cathelicidin function.
Before our study, little was known about the mechanism of
action for submicrobial doses of doxycycline, currently the
only systemic approved therapy for rosacea (Del Rosso et al.,
2007), or why the inhibition of MMPs by tetracycline
derivatives such as doxycycline leads to clinical improve-
ment in skin diseases such as acne and rosacea (Monk et al.,
2011). More than 19 MMPs are expressed in normal human
skin (Quan et al., 2009), and expression of MMP-2 and
MMP-9 is increased in rosacea skin (Jang et al., 2011). Prior
work has shown that, in rosacea, proinflammatory cytokines
trigger the release of MMPs, especially MMP-1, -3, and -9,
and lead to the degradation of extracellular matrix compo-
nents (Kahari and Saarialho-Kere, 1997) and inflammatory
damage in the form of papulopustular lesions (Golub et al.,
1998; Kang et al., 2005). Furthermore, the observations that
tetracycline derivatives are able to inhibit the activity of
various MMPs (Korting and Schollmann, 2009b) and suppress
MMP expression in human corneal epithelial cells, endothe-
lial cells, and skin keratinocytes are well documented. Until
now, however, no one has correlated the role of MMP in
LL-37 activation with the anti-inflammatory and therapeutic
effect of doxycycline. We found that through the suppression
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Figure 5. Normal human epidermal keratinocytes (NHEKs) pretreated with
doxycycline display inhibited proteolytic processing of recombinant
hCAP18. Equal amounts of recombinant cathelicidin precursor (rhCAP18,
1.525 mg) were added as indicated to identical cultures of live NHEKs either
untreated or pretreated overnight with doxycycline (225 mM). Cleavage of
hCAP18 was monitored by western blot analysis with anti-LL-37 antibody.
(a) Cathelicidin detected in whole-cell extract and (b) cathelicidin remaining
in overlying NHEK culture media. Lane 1, rhCAP18 aloneþNHEK; lane 2,
NHEK alone; lane 3, rhCAP18þ doxycyclineþNHEK; lane 4, doxycycline
aloneþNHEK. Anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is
shown as loading control. In the absence of doxycycline (lane 1), rhCAP18 is
enzymatically processed as detected by generation of a band at the expected
migration of LL-37. In the presence of doxycycline (lane 3), LL-37 is not seen
in the cell-associated fraction, and a greater amount of rhCAP18 remains in
the supernatant.
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of cutaneous and keratinocyte MMPs, and indirect inhibition
of tryptic KLKs, doxycycline can block the LL-37 proteolytic
pathway and potentially normalize LL-37 in vitro.
The correlation between in vivo doxycycline levels and the
effective concentration required to suppress MMP enzymatic
activity in vitro remains unclear. Our results confirm previous
studies that have shown that doxycycline is not a very potent
inhibitor of MMPs in comparison with other inhibitors.
According to our results, the IC50 of doxycycline for total MMPs
in the NHEKs isB100mM. The inhibition of collagenase purified
from culture media of human gingival fibroblasts (MMP-1) was
reported to require even higher doxycycline levels
(IC50¼280mM; Golub et al., 1995). The oral administration of
subantimicrobial-dose doxycycline (40mgday–1) results in a
steady-state serum level at the range of 400–600ngml–1
(Skidmore et al., 2003). These concentrations appear to be too
little to suppress MMP function. However, doxycycline is known
to show organ-specific tissue affinity that is presumably related to
its lipophilicity (Belli et al., 1968; Cars and Ryan, 1988). Thus,
the local concentration of doxycycline on the skin may be much
higher. This could be particularly evident at the air–liquid
interface of the surface of the skin where evaporation and
subsequent concentration will occur. Under these conditions it is
conceivable that the concentration of doxycycline could
approach the measured IC50. Furthermore, as our assays on
skin tape-strip samples have shown, this superficial compartment
is a site of abundant TLSP activity. Thus, both enzyme and
substrate are localized in a unique environment when soluble
concentrations are unclear. Additional work is necessary to
conclude that the action of doxycycline to inhibit MMP and
TLSP observed here is relevant to the in vivo situation.
Another implication of the present findings is in revealing
that inhibition of serine protease activity may have ther-
apeutic effect in rosacea. This observation suggests that the
use of such inhibitors could be an entirely new class of
treatment to add to the rosacea therapeutic arsenal. Prior
work from our group was the first to identify that increased
serine protease activity and cathelicidin promote skin
inflammation in rosacea (Yamasaki et al., 2007). Serine
protease inhibitors have long been used clinically to treat
excessive postoperative bleeding secondary to their ability to
inhibit both plasmin, the enzyme responsible for fibrinolysis
(McNicol and Douglas, 1964), and KLK, which leads to
inhibition of factor XIIa and the intrinsic pathway of the
coagulation cascade. This report represents the first recom-
mendation for serine protease inhibitors as a treatment
modality for rosacea secondary to our observation that they
can directly control the processing of LL-37 from hCAP18 by
tryptic KLKs, such as KLK5. These findings reveal a role,
which to our knowledge is previously unreported, for serine
protease inhibitors in epidermal homeostasis, and suggest
that they could be used to target a specific molecular cause of
the inflammation of rosacea.
MATERIALS AND METHODS
Reagents
The following reagents were purchased from Enzo Life Sciences
(Plymouth Meeting, PA): Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2
fluorogenic substrate for total-MMP enzymes and GM6001.
Boc-Phe-Ser-Arg-AMC fluorogenic substrate for TLSPs was purchased
from Bachem Bioscience (King of Prussia, PA). Tissue-purified KLK
from porcine pancreas, SB-3CT, AEBSF, and aprotinin were purchased
from Sigma-Aldrich (St Louis, MO). D-Squame standard sampling
discs were purchased from CuDerm Corporation (Dallas, TX).
Micro BCA Protein Assay Kit was purchased from Thermo Fisher
Scientific (Chicago, IL).
Tape stripping and protein extraction
This study was approved by the Human Research Protection
Program at the University of California, San Diego. Tape strips were
obtained from normal facial skin by applying and removing a single
D-Squame standard sampling disc at the same site 10 times serially.
Proteins were extracted from sampling discs by placing in
BeadBeater tubes with 1 g of 1.0mm Zirconia/Silica beads and
500ml fluorescence assay buffer. Tubes were homogenized for
3minutes with a BeadBeater homogenizer, and then centrifuged for
2minutes at 14,000 r.p.m. Protein extracts were kept on ice. Micro
BCA was performed on the protein extracts according to the
manufacturer’s instructions to determine protein concentration.
Protease activity fluorescence polarization assays
TLSP activity was assayed by extracting proteins with buffer A
composed of 0.1mM Tris-HCl (pH 8.0) and 200mM NaCl. Activity
was determined by adding TLSP-specific substrate (2.5mM) to
protein extract, incubating for 1 hour at 37 1C, and subsequently
measuring relative fluorescence units at fluorescence excitation
wavelength 354 nm and emission wavelength 422 nm.
Total-MMP activities were determined in 0.1 M Tris-HCl (pH 7.5)
containing 150mM NaCl, 0.05% (v/v) Brij35, and 0.1% (w/v)
PEG6000. For the determination of total MMP or MMP-2 activity,
both 10mM CaCl2 and 10mM ZnCl2 or 0.1mM ZnCl2 were added,
respectively, based on their dependency on metal ions as cofactors.
MMP-2 and total-MMP activity was determined by adding total-
MMP substrate (5mM) to protein extracts, incubating for 1 hour at
37 1C, and subsequently measuring relative fluorescence units at
fluorescence excitation wavelength 328 nm and emission wave-
length 400 nm. Data were normalized by protein amounts.
Total protease activities were determined with the EnzChek
Protease Assay Kit (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instruction.
Cell culture conditions
NHEKs were grown in serum-free EpiLife cell culture media
(Cascade Biologics, Portland, OR) containing 0.06mM CaCl2 and
1 EpiLife defined growth supplement at 37 1C under standard
tissue culture conditions. The cultures were maintained for up to four
passages in this media. Cell differentiation was induced by the
addition of high calcium (2mM) for 72 hours after reaching 100%
confluence.
Expression of recombinant hCAP18 in E. coli
A PCR product encoding a full length of hCAP18 was generated
by using complementary DNA obtained from NHEKs stimulated
with vitamin D as a template, the forward PCR primer (50-TAA
GGCCTCTGTCGACCAGGTCCTCAGCTACAAGGAAGC-30) and the
reverse PCR primer (50-CAGAATTCGCAAGCTTCTAGGACTCTGTCC
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TGGGTACAAG-30). The amplified DNA products were inserted into the
In-Fusion Ready pEcoli-Nterm 6HN vector (Clontech Laboratories,
Mountain View, CA) and transformed into competent cells (E. coli and
BL21 (DE3); Invitrogen). IPTG (1mM) was used to induce protein
synthesis. The expressed protein was purified with a TALON Express
Purification Kit (Clontech Laboratories). The amount of recombinant
protein was determined by BCA assay (Thermo Scientific, Rockport, IL).
SDS-PAGE and western blotting
The expression of hCAP18 protein was confirmed by SDS-PAGE
followed by western blot analysis. Gels (4–20%) were run and
transferred onto polyvinylidene difluoride membranes (Thermo
Scientific). Membranes were blocked with Odyssey infrared imaging
system blocking buffer (LI-COR, Lincoln, NE) and then probed
overnight at 4 1C with rabbit anti-LL-37 (1:1,000) primary Ab.
Membranes were washed and incubated with goat anti-rabbit IRDye
680 secondary Ab (LI-COR) for 1 hour at room temperature.
Membranes were washed, and fluorescence was detected using the
Odyssey infrared imaging system (LI-COR). Overexpressed protein
was observed at the expected size and showed immunoreactivity
against anti-LL-37 IgG. To verify equal loading of cell lysates, the
membrane was washed with Newblot polyvinylidene difluoride
stripping buffer (LI-COR) and incubated with anti-glyceraldehyde-3-
phosphate dehydrogenase mAb (1:10,000; Fitzgerald, Acton, MA),
followed by anti-mouse IRDye800 secondary Ab (LI-COR).
Processing of full-length hCAP18 to LL-37
NHEKs (100% confluent) differentiated with 72hours of 2mM calcium
conditions were pretreated with doxycycline (100mgml–1) overnight.
Full-length hCAP18 recombinant protein (1.525mg) was incubated with
doxycycline-treated NHEKs at 37 1C for 48hours. Conditioned medium
was collected and lyophilized. The sample was subsequently boiled in
Laemmli sample buffer and run by SDS-PAGE, followed by western blot
analysis with anti-LL-37 antibody. NHEKs were lysed with 80 1C
freeze/thaw cycle, boiled in Laemmli sample buffer, and run by SDS-
PAGE followed by western blot analysis with anti-LL37 IgG.
Statistical analysis
Experiments were performed at least three times, and the data are
presented as means±SE. To determine statistical significance between
groups, comparisons were made using two-tailed t-tests. For all statistical
tests, a P-value of o0.05 was accepted for statistical significance.
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